Wave Life Sciences (NASDAQ: WVE) insider transactions
In the twelve months to 10 November 2026, executives and directors of Wave Life Sciences reported 47 open-market sales of 1,122,704 shares ($16.2m) and 6 open-market purchases of 10,243,496 shares ($82.6m), by 13 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 5 October 2026 | Wagner Heidi L | Director | Grant or award | +10,700 | — | 55,630 | Form 4 |
| 5 October 2026 | Henry Christian O | Director | Grant or award | +10,700 | — | 23,400 | Form 4 |
| 5 October 2026 | Rawcliffe Adrian | Director | Grant or award | +10,700 | — | 10,700 | Form 4 |
| 5 October 2026 | Corrigan Mark | Director | Grant or award | +10,700 | — | 39,515 | Form 4 |
| 5 October 2026 | Takanashi Ken | Director | Grant or award | +10,700 | — | 30,779 | Form 4 |
| 5 October 2026 | Tan Aik Na | Director | Grant or award | +10,700 | — | 35,668 | Form 4 |
| 5 October 2026 | Verdine Gregory L. | Director | Grant or award | +10,700 | — | 200,917 | Form 4 |
| 5 October 2026 | Ra Capital Management, L.p. | Director | Grant or award | +10,700 | — | 39,515 | Form 4 |
| 12 August 2026 | Rawcliffe Adrian | Director | Open-market sale | −12,700 | $5.29 | 0 | Form 4 |
| 11 August 2026 | Tan Aik Na | Director | Open-market sale | −432 | $6.01 | 24,968 | Form 4 |
| 11 August 2026 | Takanashi Ken | Director | Open-market sale | −3,864 | $6.01 | 20,079 | Form 4 |
| 11 August 2026 | Wagner Heidi L | Director | Option exercise | +7,000 | $5.97 | 51,930 | Form 4 |
| 11 August 2026 | Wagner Heidi L | Director | Open-market sale | −7,000 | $6.01 | 44,930 | Form 4 |
| 30 March 2026 | Ra Capital Management, L.p. | Director | Open-market purchase | +971,091 | $6.50 | 26,975,505 | Form 4 |
| 27 March 2026 | Ra Capital Management, L.p. | Director | Open-market purchase | +2,495,623 | $6.43 | 26,004,414 | Form 4 |
| 26 March 2026 | Ra Capital Management, L.p. | Director | Open-market purchase | +4,954,558 | $6.06 | 23,157,567 | Form 4 |
| 26 March 2026 | Ra Capital Management, L.p. | Director | Open-market purchase | +351,224 | $6.38 | 23,508,791 | Form 4 |
| 23 March 2026 | Takanashi Ken | Director | Conversion | +3,901,348 | — | 9,606,408 | Form 4 |
| 26 February 2026 | Francis Chris | See Remarks | Option exercise | +17,900 | $3.87 | 79,767 | Form 4 |
| 26 February 2026 | Francis Chris | See Remarks | Open-market sale | −17,900 | $15.09 | 61,867 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Wave Life Sciences page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.